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Abstract 
This case history describes a rare complaint - Calciphylaxis, seen in a New Zealand Maori 
patient undergoing renal dialysis. This condition causes non-healing tissue ulceration, 
typically with sepsis and is associated with a very high mortality rate. The need for vigilance 
among health professionals is highlighted, including the risk factors that may faciliate an 
early diagnosis; together with the value associated with a multi-disciplinary team approach to 
management. 
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1 Introduction 
Calciphylaxis or calcific uremic arteriolopathy (CUA) is a rare, but potentially devastating 
complication that almost exclusively affects patients undergoing dialysis for renal failure 
(stage 5 chronic kidney disease or CKD-5). [1]  We report a case of calciphyaxis in a New 
Zealand Maori patient with CKD-5. 
2 Case history 
A 66 year-old female patient of New Zealand Maori ethnicity with CKD-5 secondary to 
complicated type-two diabetes mellitus was seen at the multidisciplinary clinic for 
assessment of recent leg ulceration.  She was undergoing haemodialysis (3x/week) and had 
a background of Peripheral Vascular Disease with right below knee amputation and stenting 
of the the left superficial femoral artery in the preceding 12 months.  A small black eschar 
was first noted over the lateral aspect of the leg.  This lesion rapidly progressed to an 
irregular shaped, necrotic spreading ulceration with black eschar formation and violaceous 
peri-wound tissue (Livedo Reticularis) over 2-3 weeks.  The lesion was mildly malodourous, 
very painful and wound depth was difficult to determine (Figure 1).  
 
Figure 1 – Presentation of ulceration 
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Surgical debridement and biopsy was undertaken and intra-venous (IV) antibiotics instigated 
(Gentamicin) to combat any super-added infection.  Calciphylaxis was suspected on the 
basis of patient profile and clinical features.  Histology of specimens indicated “underlying 
granulation tissue, fibrosis, chronic inflammation and scattered calcifications within the 
superficial and deep dermis” were consistent with Calciphylaxis.  Unusually calcium and 
phosphate levels remained normal, where increased levels might normally be expected.  A 
summary of additonal tests are presented in Table 1.  
Table 1 – Clinical characterisitcs 
Characterisitic Value Range 
Sodium 139 mmol/L  135-145 
Potassium 3.1 mmol/L 3.5-5.2 
Chloride 96 mmol/L 95-110 
Glucose 6.1 mmol/L 3.0-11.0 
Urea 10.2 mmol/L 3.2-7.7 
Creatinine 440 mmol/L 45-90 
Urate 0.22 mmol/L 0.14-0.36 
Phosphate 0.91 mmol/L 0.70-1.50 
Calcium (ablumin adjusted) 2.50 mmol/L 2.1-2.6 
Albumin 28 g/L  38-52 
Magnesium 0.77 mmol/L  0.70-1.00 
CRP 154 <5 
Haemoglobin 84 g/L 115-155 
RBC 2.99 xE12/L 3.6-5.6 
Haematocrit 0.27 0.35-0.46 
Mean cell volume 90 fL 80-99 
Mean cell haemoglobin 28.1 pg 27-33 
RDW 14.7 11.5-15.0 
Platelets 383 xE9/L 150-400 
MPV 9.2 fL 9.0-12.2 
WBC 17.2 xE9/L  4.0-11.0 
Neutrophils 17.2 xE9/L 1.9-7.5 
Eosinophils 17.2 xE9/L 0-0.5 
Monocytes 17.2 xE9/L 0.2-1.0 
Lymphocytes 1.5  xE9/L 1.0-4.0 
 
Our patient’s foot pulses were not palpable and monophasic on Doppler capture.  Duplex 
scan confirmed the recently stented artery remained patent, although there was extensive 
untreatable arterial disease in the arteries further down the leg, with no vessel reaching the 
foot uninterrupted. Despite the latter, there was no clinical evidence of critical limb 
ischaemia.  However, with little sign of improvement, further surgical debridement was 
undertaken three weeks later together with continued IV antibiotics.  Tissue culture isolated 
heavy growths of gram negative bacilli and Pseudomonas Aeruginosa and Enterobacter 
Clocae complex.  Given the range of bactera isolated, the ultra broad spectrum antibiotic 
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Metropenem IV was added to Gentamicin, to give broader cover.  Additionally, Sodium 
Thiosulphate infusions were undertaken to manage the severe metabolic acidosis that can 
accompany Calciphylaxis. 
In spite of surgical debridements, IV antibiotics and sodium thiosulphate over the following 
two weeks, the patient developed extensive spreading necrosis and sepsis requiring a left 
above knee amputation.  After a prolonged period of rehabilitation (12 weeks) she recovered 
enough to return home and remains surprisingly positive and well. 
 
3 Discussion 
Calciphylaxis is a rare complication seen in patients with CKD-5 undergoing Haemodialysis 
with a reported prevalence of 1-4% [1].  Lesions are most commonly noted on the legs, but 
may occur on upper limbs or trunk [2,3].  While the precise aetiology of Calciphylaxis 
remains unknown, the pathology is caused by calcium deposits in the microvascular network 
causing vascular obstruction [2,4].  The subsequent ischeamia causes necrosis of skin and 
fatty tissue with associated vascular calcifications and thrombosis [2,3].  These changes lead 
to  non-healing tissue ulceration and  sepsis with very high mortality rate (60-80%); 
overwhelming sepsis being the main cause of death [5]. 
3.1 Clinical presentation and diagnosis 
The initial presentation, as noted in this case, is typically painful mottling of skin,  sometimes 
precipitated by minor trauma, occasionally with haematoma. Underlying necrosis can be 
deep, even in early stages.  A variety of risk factors are reported (Box 1). Our patient was 
female, in whom Calciphylaxis is more common [6], but notably not of Caucasian ethnicity. 
Calciphlyaxis has rarely been reported in Maori populations, diabetes and CKD-5 were other 
key risk factors.  Recognising these risk factors together with vilgilance associated with new 
lesion formation represents the best chance for early diagnosis. [6] 
Box 1 – Risk factors for Calciphylaxis [3,7] 
Female gender 
Caucasian ethnicity 
Diabetes  
End Stage Renal Failure 
Increasing time on renal dialysis 
Hyperparathyroidism 
Hyperphosphatemia 
Hypercalcamia 
Calcium supplementation 
History of protein C or S deficiency 
Liver disease 
Warfarin or corticosteroid therapy 
Obesity 
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An increase in Calciphylaxis is reported over recent years, which may represent a true 
increase in prevalence due to greater levels of chronic kidney disease with a range of 
underpinning aetiology (e.g. obesity, diabetes and aging population in western societies) 
and/or an increased clinical recognition [8].  People with Maori and Pacific island heritage 
have a greater incidence of CKD-5 in comparison to the rest of the population – particularly 
in relation to diabetes; typically these groups also suffer from  poorer outcomes [9-11]. As 
Calciphylaxis is almost exclusively seen in CKD-5, consequently a higher index of suspicion 
is required by clinicians managing these populations; particularly in respect of early 
recognition and management.  Blood tests did not reveal any apparent dysregulation in 
calcium or potassium levels.  Recent reviews [6] indicate other isolated case reports with 
similar findings suggesting a need for further investigation in larger observation studies.   
 
Diagnosis is initally based on clinical appearance and history [5]. Tests for elevated 
calcium/phosphate and parathyroid hormone levels may aid the clinical picture, but remained 
normal in this case [5,8]. However, particularly in dialysed patients calciphylaxis can occur 
when calcium and phosphate levels are normal [12].  Wong et al. [10] found deep tissue 
biopsy more helpful than punch biopsy, histological examination remaining the gold standard 
for diagnosis [3].  However, biopsy may also lead to new lesion formation [6,14].  Drawing 
these aspects together, Hayashi et al.[5] proposed a diagnostic criteria.  Key differential 
diagnosis (owing to their similar clinical appearance) include warfarin-induced skin necrosis, 
cholesterol embolisation, pyoderma gangrenosum and primary vasculitis [15-17]. The history 
in this case did not indicate these alternatives.  Where Calciphylaxis is suspected in the 
absence of renal disease other co-morbidities (e.g. primary hyperparathyroidism, liver 
disease, and inflammatory arthritis) can lead to a higher index for suspicion [7,10,18]. 
3.2 Management 
There appears little consensus in the literature regarding management although a multi-
disciplinary approach that can incorporate wound and pain management, improved 
biochemical paraemters and pharmacological management are thought to be key [2,19,20].  
Controlling infection, with a low threshold for broad spectrum antibiotic therapy and 
managing pain are primary considerations, together with improving arterial supply where 
necessary, often in conjunction with surgical debridement [4,6].  However, surgical 
debribement is controversial owing to vasculopathy [2,15]. Debridement reportedly increases 
one-year survival rates [21], but requires experienced teams owing to the complexity of 
these wounds [6,22]. If only a dry black eschar and no ulcer or infection are present, it may 
be better to not debride as this could worsen the condition.  Typically aggressive wound care 
is required, which may include hyperbaric oxygen where vascular perfusion is poor and re-
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vascularisation not possible [2].  Additionally, opioid-based analgesia may be required to 
facilitate optimal wound care as these wounds are often very painful [3]. In our case Sodium 
Thiosulphate infusion (previously used for cyanide poisoning) was instituted to manage the 
toxicity associated with spreading infection.  Nigwekar and colleagues reported considerable 
clinical benefit from Sodium Thiosulphate infusion in a cohort of 172 patients with 
Calciphylaxis [23].  Alternatviely, Bisphosphonates (e.g. Pamidronate infusion) have 
reportedly been used with some success in decreasing mineralisation and reducing pro-
inflammatory cytokines [3].  
Where indicated, the normalisation of calcium/phosphate and parathyroid hormone levels 
where indicated is helpful.  A range of options are available to faciliate this, including 
increasing the number of dialysis sessions and/or parathyroidectomy [3,7],  but was not 
required in this example.  More recently, success with Cinacalet (a calcimimetic agent) as a 
first line treatment have been reported [24].   
However, the uncommon nature of calciphylaxis coupled with an incomplete understanding 
of the pathogenesis have limited the options for high quality controlled trials, with most of the 
available knowledge derived from case series.  
 
4 Conclusion 
Calciphylaxis is a rare, but potentially devastating complication associated with a high 
mortality rate, most commonly seen in renal failure.  We highlight the need for vigulence 
among health professionals who treat patients at risk of calciphylaxis to facilitate early 
diagnosis and mullti-disciplinary management, which incorporates wound care, pain 
management, surgical debridement, and dialysis as well as mimising risk factors as 
Calciphylaxis often has an unfavourable prognosis. 
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Highlights 
• Calciphylaxis is a rare complication with high mortality seen in renal failure 
 
• Vigulence is needed to facilitate early diagnosis 
 
• Mullti-disciplinary management is key to reducing morbidity and mortality 
